ClinicalTrials.gg
CompletedNCT00574249BELIEVEUpdated Apr 13, 2011Results posted

Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment

A Phase 3 interventional study of adalimumab and Calcipotriol/Betamethasone Ointment in Chronic Plaque Psoriasis, sponsored by Abbott. Completed at 131 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-13.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
730
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
9th of 47
730 · median 200
Started
2007
with 1 other
Phase 3
17 of 47
none open now
Registered
11th of 47
by date
Lead sponsor
1 of 47
Abbott

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 9th largest by enrollment, is one of 2 that started in 2007, is one of 17 in phase 3, and was the 11th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

The objective of this study is to assess the efficacy and safety of adalimumab in combination with topical psoriasis treatment, calcipotriol/betamethasone, vs. adalimumab in combination with matching vehicle in subjects with moderate to severe chronic plaque psoriasis.

Read the detailed description

Additional information regarding sponsors: Abbott GmbH \& Co. KG is sponsor for EU member states. Abbott US is sponsor for non-EU member states.

03

Conditions studied

  • Chronic Plaque Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • Moderate Psoriasis
  • Severe Psoriasis
  • Chronic Plaque Psoriasis
  • Severe Chronic Plaque Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is >= 18 years of age
  • Subject had a clinical diagnosis of chronic plaque psoriasis for at least 6 months, and has moderate to severe plaque psoriasis
  • Subject must have been treated and failed to respond to, or has a to, or is intolerant to at least two different systemic therapies, one of which must be cyclosporine, or methotrexate or oral PUVA
  • Subject is judged to be in generally good health as determined by the principal investigator

Exclusion criteria

Exclusion Criteria:

  • Subject has previous exposure to adalimumab
  • Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy
  • Subject is taking or requires oral or injectible
  • Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, medication-induced or medication-exacerbated psoriasis or new onset guttate psoriasis
  • Subject considered by the investigator, for any reason, to be an unsuitable candidate
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant
  • Subject has a calcium metabolism disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
730 participants (actual)

Study arms

  • Active comparator
    adalimumab + placebo

    adalimumab + placebo (vehicle ointment)

    Biological: adalimumab · Drug: placebo (vehicle ointment)

  • Active comparator
    adalimumab + calcipotriol/betamethasone

    adalimumab + calcipotriol/betamethasone ointment

    Biological: adalimumab · Drug: Calcipotriol/Betamethasone Ointment

Interventions

  • Biologicaladalimumab

    subcutaneous injection using prefilled pen/syringe, solution containing 40 mg in 0.8 milliliters; 2 injections given at Baseline (Day 1) then once every other week from Weeks 1 though 15

    Also known as: ABT-D2E7, Humira

  • DrugCalcipotriol/Betamethasone Ointment

    Drug pages: Calcipotriene · Betamethasone

    Topical ointment (calcipotriol 50 mcg/g and betamethasone 500 mcg/g) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16

    Also known as: Daivobet

  • Drugplacebo (vehicle ointment)

    Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieve a PASI75 Response at Week 16 Compared With Baseline (Week 0)

    PASI75 is defined as at least a 75% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement being 100%. The outcome measure is the percentage of participants who had at least a 75% PASI score decrease.

    Time frame: Week 0 and Week 16

Secondary outcomes

  1. Percentage of Participants With a PASI50 Response at Week 16 Compared With Baseline (Week 0)

    PASI50 is defined as at least a 50% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement 100%. The outcome measure is the percentage of participants who had at least a 50% PASI score decrease.

    Time frame: Week 0 and Week 16

  2. Percentage of Participants With a PASI90 Response at Week 16 Compared With Baseline (Week 0)

    PASI90 is defined as at least a 90% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement 100%. The outcome measure is the percentage of participants who had at least a 90% PASI score decrease.

    Time frame: Week 0 and Week 16

  3. Percentage of Participants With a PASI100 Response at Week 16 Compared With Baseline (Week 0)

    PASI100 is defined as at least a 100% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst) with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement 100%. The outcome measure is the percentage of participants who had at least a 100% PASI score decrease.

    Time frame: Week 0 and Week 16

  4. Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 2

    PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).

    Time frame: Week 2

  5. Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 4

    PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).

    Time frame: Week 4

  6. Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 8

    PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).

    Time frame: Week 8

  7. Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 12

    PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).

    Time frame: Week 12

  8. Percentage of Participants Achieving a Physicians Global Assessment (PGA) Response of Clear or Minimal at Week 16

    PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).

    Time frame: Week 16

  9. Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16 Compared With Baseline (Week 0)

    DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.

    Time frame: Week 0 and Week 16

  10. Percent Change in the Dermatology Life Quality Index (DLQI) Total Score at Week 2 Compared With Baseline (Week 0)

    DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.

    Time frame: Week 0 and Week 2

  11. Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 4 Compared With Baseline (Week 0)

    DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.

    Time frame: Week 0 and Week 4

  12. Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 8 Compared With Baseline (Week 0)

    DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.

    Time frame: Week 0 and Week 8

  13. Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 12 Compared With Baseline (Week 0)

    DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.

    Time frame: Week 0 and Week 12

  14. Percent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 16 Compared With Baseline (Week 0)

    Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) is a participant-reported outcome that employs a questionnaire that asks for the participant's views about their health. Percent change at Week 16 is calculated as (Week 16 SF-36 PCS minus Week 0 SF-36 PCS) divided by Week 0 SF-36 PCS. Positive percent change in score indicates improvement, with best improvement 100%.

    Time frame: Week 0 and Week 16

  15. Percent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 8 Compared With Baseline (Week 0)

    Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) is a participant-reported outcome that employs a questionnaire that asks for the participant's views about their health. Percent change at Week 8 is calculated as (Week 8 SF-36 PCS minus Week 0 SF-36 PCS) divided by Week 0 SF-36 PCS. Positive percent change in score indicates improvement, with best improvement 100%.

    Time frame: Week 0 and Week 8

Other outcomes

  1. Percent Change in Psoriasis Scalp Severity Index (PSSI) From Baseline to Week 16.

    PSSI is a physician assessment of clinical symptoms of scalp psoriasis. Computed as the sum of scores for erythema, induration, and desquamation (1 = absent; 4 = severest possible) multiplied by involved area (0 = 0%; 6 = 90-100%). Total score range: 0 (best) to 72 (worst). Negative change and percent change from Baseline indicate improvement.

    Time frame: Week 0 and Week 16

  2. Percent Change in Nail Psoriasis Severity Index (NAPSI) at Week 16.

    NAPSI is a sum of 2 scores that grade nail matrix psoriasis (based on presence/absence of pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (based on presence/absence of onycholysis splinter hemorrhages, oil drop \[salmon patch\] discoloration, and nail bed hyperkeratosis). Each fingernail is given a single score based on presence of psoriasis in quadrant of nail: 0 (none) to 4 (present in 4/4 nail quadrants). Score range: 0 (best) to 80 (worst). Negative change and percent change from Baseline indicate improvement.

    Time frame: Week 0 and Week 16

07

Results

Posted Jan 18, 2010

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Started364366
Completed338338
Not completed2628
Withdrew: Adverse event618
Withdrew: Lack of efficacy53
Withdrew: Lost to follow-up43
Withdrew: Protocol violation52
Withdrew: History of carcinoma10
Withdrew: Withdrawal by subject30
Withdrew: Physician decision10
Withdrew: Pregnancy10
Withdrew: Excluded by company01
Withdrew: Ppd test taken twice01

Outcome measures

PrimaryPercentage of Participants Who Achieve a PASI75 Response at Week 16 Compared With Baseline (Week 0)

PASI75 is defined as at least a 75% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement being 100%. The outcome measure is the percentage of participants who had at least a 75% PASI score decrease.

Time frame:
Week 0 and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve a PASI75 Response at Week 16 Compared With Baseline (Week 0)
percentage of participantsAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percentage of Participants Who Achieve a PASI75 Response at Week 16 Compared With Baseline (Week 0)70.964.8
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · Cochran-Mantel-Haenszel · p = 0.086 (Level of significance 5%; no adjustment for multiple comparisons necessary.)Two-sided CMH test stratified by country at the alpha level 0.05. Centers were pooled by country (Sweden and Finland pooled due to few participants).
SecondaryPercentage of Participants With a PASI50 Response at Week 16 Compared With Baseline (Week 0)

PASI50 is defined as at least a 50% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement 100%. The outcome measure is the percentage of participants who had at least a 50% PASI score decrease.

Time frame:
Week 0 and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI50 Response at Week 16 Compared With Baseline (Week 0)
percentage of participantsAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percentage of Participants With a PASI50 Response at Week 16 Compared With Baseline (Week 0)82.780.9
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · Fisher Exact · p = 0.565
SecondaryPercentage of Participants With a PASI90 Response at Week 16 Compared With Baseline (Week 0)

PASI90 is defined as at least a 90% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement 100%. The outcome measure is the percentage of participants who had at least a 90% PASI score decrease.

Time frame:
Week 0 and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI90 Response at Week 16 Compared With Baseline (Week 0)
percentage of participantsAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percentage of Participants With a PASI90 Response at Week 16 Compared With Baseline (Week 0)50.338.8
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · Fisher Exact · p = 0.002
SecondaryPercentage of Participants With a PASI100 Response at Week 16 Compared With Baseline (Week 0)

PASI100 is defined as at least a 100% reduction in PASI (Psoriasis Area and Severity Index) score compared with the Baseline PASI score. PASI scores range from 0.0 (best) to 72.0 (worst) with the highest score representing complete erythroderma of the severest degree. The percent decrease in score is calculated as (Week 0 PASI score minus Week 16 PASI score) divided by Week 0 PASI score. Positive percent decreases indicate improvement, with best improvement 100%. The outcome measure is the percentage of participants who had at least a 100% PASI score decrease.

Time frame:
Week 0 and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a PASI100 Response at Week 16 Compared With Baseline (Week 0)
percentage of participantsAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percentage of Participants With a PASI100 Response at Week 16 Compared With Baseline (Week 0)24.215.3
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · Fisher Exact · p = 0.003
SecondaryPercentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 2

PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).

Time frame:
Week 2
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 2
percentage of participantsAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 27.113.9
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · Fisher Exact · p = 0.004
SecondaryPercentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 4

PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 4
percentage of participantsAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 424.533.1
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · Fisher Exact · p = 0.011
Other pre-specifiedPercent Change in Psoriasis Scalp Severity Index (PSSI) From Baseline to Week 16.

PSSI is a physician assessment of clinical symptoms of scalp psoriasis. Computed as the sum of scores for erythema, induration, and desquamation (1 = absent; 4 = severest possible) multiplied by involved area (0 = 0%; 6 = 90-100%). Total score range: 0 (best) to 72 (worst). Negative change and percent change from Baseline indicate improvement.

Time frame:
Week 0 and Week 16
Reported as:
Median · percent change in score
Percent Change in Psoriasis Scalp Severity Index (PSSI) From Baseline to Week 16.
percent change in scoreAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percent Change in Psoriasis Scalp Severity Index (PSSI) From Baseline to Week 16.-100.00 (-100.0 to -87.5)-100.00 (-100.0 to -80.0)
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · ANOVA · p = 0.204 · Mean difference (net): 9.74 · 95% CI -5.30 to 24.78One-way ANOVA. For confidence interval and difference estimate, adalimumab + calcipotriol/betamethasone minus adalimumab + placebo was used.
Other pre-specifiedPercent Change in Nail Psoriasis Severity Index (NAPSI) at Week 16.

NAPSI is a sum of 2 scores that grade nail matrix psoriasis (based on presence/absence of pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (based on presence/absence of onycholysis splinter hemorrhages, oil drop \[salmon patch\] discoloration, and nail bed hyperkeratosis). Each fingernail is given a single score based on presence of psoriasis in quadrant of nail: 0 (none) to 4 (present in 4/4 nail quadrants). Score range: 0 (best) to 80 (worst). Negative change and percent change from Baseline indicate improvement.

Time frame:
Week 0 and Week 16
Reported as:
Median · percent change in score
Percent Change in Nail Psoriasis Severity Index (NAPSI) at Week 16.
percent change in scoreAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percent Change in Nail Psoriasis Severity Index (NAPSI) at Week 16.-40.00 (-66.7 to 0.0)-37.50 (-68.4 to 0.0)
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · ANOVA · p = 0.272 · Mean difference (net): -17.55 · 95% CI -48.92 to 13.82One-way ANOVA. Confidence interval and difference estimated from adalimumab + calcipotriol/betamethasone minus adalimumab + placebo.
SecondaryPercentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 8

PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 8
percentage of participantsAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 846.242.9
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · Fisher Exact · p = 0.413
SecondaryPercentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 12

PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 12
percentage of participantsAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 1264.850.0
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · Fisher Exact · p = <0.001
SecondaryPercentage of Participants Achieving a Physicians Global Assessment (PGA) Response of Clear or Minimal at Week 16

PGA is a physician's assessment of severity of disease (grading lesion severity). PGA scores range from 0 (best) to 6 (worst): on the 6-point scale, a score of 0 = Clear and a score of 6 = Very Severe for the lesion severity. PGA Clear (0) is no plaque elevation over normal skin and no scale with or without erythema. Minimal (1) is possible plaque elevation but difficult to ascertain a slight elevation above normal skin. Percentage of participants: 0% to 100% (best).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Physicians Global Assessment (PGA) Response of Clear or Minimal at Week 16
percentage of participantsAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percentage of Participants Achieving a Physicians Global Assessment (PGA) Response of Clear or Minimal at Week 1664.656.6
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · Fisher Exact · p = 0.028
SecondaryPercent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16 Compared With Baseline (Week 0)

DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.

Time frame:
Week 0 and Week 16
Reported as:
Mean · percent change in score
Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16 Compared With Baseline (Week 0)
percent change in scoreAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16 Compared With Baseline (Week 0)-71.46 ± 49.171-67.20 ± 45.463
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · ANOVA · p = 0.228One-way ANOVA.
SecondaryPercent Change in the Dermatology Life Quality Index (DLQI) Total Score at Week 2 Compared With Baseline (Week 0)

DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.

Time frame:
Week 0 and Week 2
Reported as:
Mean · percent change in score
Percent Change in the Dermatology Life Quality Index (DLQI) Total Score at Week 2 Compared With Baseline (Week 0)
percent change in scoreAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percent Change in the Dermatology Life Quality Index (DLQI) Total Score at Week 2 Compared With Baseline (Week 0)-32.14 ± 44.118-47.49 ± 41.093
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · ANOVA · p = < 0.001One-way ANOVA.
SecondaryPercent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 4 Compared With Baseline (Week 0)

DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.

Time frame:
Week 0 and Week 4
Reported as:
Mean · percent change in score
Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 4 Compared With Baseline (Week 0)
percent change in scoreAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 4 Compared With Baseline (Week 0)-46.64 ± 68.139-60.93 ± 38.122
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · ANOVA · p = 0.001One-way ANOVA.
SecondaryPercent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 8 Compared With Baseline (Week 0)

DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.

Time frame:
Week 0 and Week 8
Reported as:
Mean · percent change in score
Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 8 Compared With Baseline (Week 0)
percent change in scoreAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 8 Compared With Baseline (Week 0)-63.30 ± 45.404-62.30 ± 43.087
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · ANOVA · p = 0.764One-way ANOVA.
SecondaryPercent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 12 Compared With Baseline (Week 0)

DLQI is a participant-reported outcome consisting of a set of 10 questions regarding the degree to which (i.e., how much) the subject's skin has affected certain behaviors and quality of life over the last week. Responses to each are: very much, a lot, a little, or not at all. Total score range: 0 (best) to 30 (worst). Negative change and percent change from Baseline indicate improvement, with best improvement -100%.

Time frame:
Week 0 and Week 12
Reported as:
Mean · percent change in score
Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 12 Compared With Baseline (Week 0)
percent change in scoreAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 12 Compared With Baseline (Week 0)-69.49 ± 45.030-66.75 ± 49.195
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · ANOVA · p = 0.437One-way ANOVA.
SecondaryPercent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 16 Compared With Baseline (Week 0)

Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) is a participant-reported outcome that employs a questionnaire that asks for the participant's views about their health. Percent change at Week 16 is calculated as (Week 16 SF-36 PCS minus Week 0 SF-36 PCS) divided by Week 0 SF-36 PCS. Positive percent change in score indicates improvement, with best improvement 100%.

Time frame:
Week 0 and Week 16
Reported as:
Mean · percent change in score
Percent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 16 Compared With Baseline (Week 0)
percent change in scoreAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 16 Compared With Baseline (Week 0)20.53 ± 31.60319.71 ± 32.136
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · ANOVA · p = 0.740One-way ANOVA.
SecondaryPercent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 8 Compared With Baseline (Week 0)

Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) is a participant-reported outcome that employs a questionnaire that asks for the participant's views about their health. Percent change at Week 8 is calculated as (Week 8 SF-36 PCS minus Week 0 SF-36 PCS) divided by Week 0 SF-36 PCS. Positive percent change in score indicates improvement, with best improvement 100%.

Time frame:
Week 0 and Week 8
Reported as:
Mean · percent change in score
Percent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 8 Compared With Baseline (Week 0)
percent change in scoreAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
Percent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 8 Compared With Baseline (Week 0)19.35 ± 30.26418.22 ± 29.967
Statistical analysis
  • Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone · ANOVA · p = 0.634One-way ANOVA.

Adverse events

Collected over Overall study. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab + Placebo—15/364 (4.1%)124/364 (34.1%)
Adalimumab + Calcipotriol/Betamethasone—16/366 (4.4%)136/366 (37.2%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
abortion infectedInfections and infestations1/1130/116
dermatitis exfoliativeSkin and subcutaneous tissue disorders2/3640/366
pneumoniaInfections and infestations0/3642/366
angina pectorisCardiac disorders1/3640/366
anaphylatic shockImmune system disorders1/3640/366
bronchopneumoniaInfections and infestations1/3640/366
erysipelasInfections and infestations1/3641/366
staphylococcal infectionInfections and infestations1/3640/366
musculoskeletal painMusculoskeletal and connective tissue disorders1/3640/366
lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3640/366
Most frequent other events
Showing 10 of 17
Most frequent other events
EventAdalimumab + PlaceboAdalimumab + Calcipotriol/Betamethasone
NasopharyngitisInfections and infestations23/36432/366
HeadacheNervous system disorders22/36419/366
PruritusSkin and subcutaneous tissue disorders21/36413/366
PsoriasisSkin and subcutaneous tissue disorders17/36419/366
CoughRespiratory, thoracic and mediastinal disorders12/36411/366
PharyngitisInfections and infestations12/3647/366
NauseaGastrointestinal disorders5/36412/366
DiarrhoeaGastrointestinal disorders7/36411/366
ArthralgiaMusculoskeletal and connective tissue disorders7/36411/366
RhinitisInfections and infestations10/3644/366

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Adalimumab + PlaceboAdalimumab + Calcipotriol/BetamethasoneTotal
<=18 years011
Between 18 and 65 years343350693
>=65 years211536
Age Continuous
Age Continuous(years)Adalimumab + PlaceboAdalimumab + Calcipotriol/BetamethasoneTotal
Mean44.8 ± 12.6145.3 ± 11.9545.1 ± 12.28
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab + PlaceboAdalimumab + Calcipotriol/BetamethasoneTotal
Female113116229
Male251250501
Region of Enrollment
Region of Enrollment(participants)Adalimumab + PlaceboAdalimumab + Calcipotriol/BetamethasoneTotal
Austria121224
Belgium403676
Czech Republic81018
Denmark151530
Finland5611
France5861119
Germany7983162
Greece121224
Italy323466
Netherlands171835
Spain332659
Sweden9817
Switzerland121022
Turkey141428
United Kingdom182139
08

Study locations

131 sites
  • Graz, 8036, Austria
  • Innsbruck, 6020, Austria
  • Salzburg, 5020, Austria
  • Wein, 1160, Austria
  • Wien, 1030, Austria
  • Wien, 1090, Austria
  • Aalst, 9300, Belgium
  • Brugge, 8000, Belgium
  • Brussel, 1090, Belgium
  • Bruxelles, 1070, Belgium
  • Bruxelles, 1200, Belgium
  • Edegem, 2650, Belgium
  • Geel, 2440, Belgium
  • Gent, 9000, Belgium
  • Kortrijk, 8500, Belgium
  • Leuven, 3000, Belgium
  • Liege, 4000, Belgium
  • Mons, 7000, Belgium
  • Brno, 65691, Czech Republic
  • Hradec Kralove, 500 05, Czech Republic
  • Prague, 11000, Czech Republic
  • Arhus C, 8000, Denmark
  • Copenhagen, 2400, Denmark
  • Hellerup, 2900, Denmark
  • Herning, 7400, Denmark
  • Helsinki HUS, 00029, Finland
  • Jyvaskyla, 40620, Finland
  • Lahti, 15850, Finland
  • Brest Cedex, 29609, France
  • Creteil Cedex, 94010, France
  • Lille Cedex, 59037, France
  • Limoges Cedex, 87042, France
  • Montpellier Cedex 5, 34295, France
  • Nancy, 54000, France
  • Nice Cedex 3, 06202, France
  • Paris Cedex 10, 75475, France
  • Pessac, 33604, France
  • Pierre Benite Cedex, 69310, France
  • Rouen, 76031, France
  • St Etienne Cedex 2, 42055, France
  • Toulouse Cedex 9, 31059, France
  • Berlin, 10117, Germany
  • Berlin, 10827, Germany
  • Buchholz Nordheide, 21244, Germany
  • Dresden, 01067, Germany
  • Dresden, 01307, Germany
  • Dusseldorf, 40225, Germany
  • Erlangen, 91052, Germany
  • Frankfurt, 60590, Germany
  • Freiburg, 79104, Germany
  • Gottingen, 37075, Germany
  • Halle Saale, 06097, Germany
  • Hamburg, 20246, Germany
  • Hamburg, 20354, Germany
  • Hannover, 30449, Germany
  • Heidelberg, 69115, Germany
  • Jena, 07740, Germany
  • Kiel, 24150, Germany
  • Koln, 50924, Germany
  • Leipzig, 04103, Germany
  • Magdeburg, 39120, Germany
  • Mainz, 55101, Germany
  • Munchen, 80337, Germany
  • Munster, 48149, Germany
  • Oldenburg, 26133, Germany
  • Osnabruck, 49078, Germany
  • Potsdam, 14480, Germany
  • Regensburg, 93053, Germany
  • Rostock, 18055, Germany
  • Tubingen, 72076, Germany
  • Athens, 16121, Greece
  • Crete, 71201, Greece
  • Benevento, 82100, Italy
  • Catania, 95124, Italy
  • Catanzaro, 88100, Italy
  • Coppitto-L'Aquila, 67100, Italy
  • Firenze, 50119, Italy
  • Messina, 98200, Italy
  • Milano, 20161, Italy
  • Modena, 41100, Italy
  • Padova, 35128, Italy
  • Palermo, 90127, Italy
  • Roma, 0133, Italy
  • Amsterdam, 1105 AZ, Netherlands
  • Breda, 4818 CK, Netherlands
  • Maastricht, 6229 HX, Netherlands
  • Nijmegen, 6525 GL, Netherlands
  • Rotterdam, 3015 CA, Netherlands
  • Alicante, 03010, Spain
  • Barcelona, 08025, Spain
  • Barcelona, 08036, Spain
  • Barcelona, 08916, Spain
  • Bilbao, 48013, Spain
  • Bilbao, 48903, Spain
  • Galdacano Vizcaya, 48960, Spain
  • Granada, 18012, Spain
  • Las Palmas de Gran Canarias, 35010, Spain
  • Madrid, 28006, Spain
  • Madrid, 28034, Spain
  • Madrid, 28041, Spain

Showing the first 100 of 131 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Paul C, van de Kerkhof P, Puig L, Unnebrink K, Goldblum O, Thaci D. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. Eur J Dermatol. 2012 Nov-Dec;22(6):762-9. doi: 10.1684/ejd.2012.1863. PubMed 23178916 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007 and a primary completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2007
First posted
Dec 17, 2007
Start
Nov 2007
Primary completionActual
Oct 2008
Results first posted
Jan 18, 2010
Last update
Apr 13, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00574249
Lead sponsor
Abbott
First posted
Dec 17, 2007
Start date
Nov 2007
Primary completion
Oct 2008
Results posted
Jan 18, 2010
Last update
Apr 13, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Betamethasone

Start the discussion